84 related articles for article (PubMed ID: 21076378)
1. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients.
Snydman DR; Kistler KD; Ulsh P; Morris J
Transplantation; 2010 Dec; 90(12):1432-8. PubMed ID: 21076378
[TBL] [Abstract][Full Text] [Related]
2. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database.
Snydman DR; Kistler KD; Ulsh P; Bergman GE; Vensak J; Morris J
Clin Transplant; 2011; 25(4):E455-62. PubMed ID: 21504474
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
5. The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation.
Fisher RA; Kistler KD; Ulsh P; Bergman GE; Morris J
Transpl Infect Dis; 2012 Apr; 14(2):121-31. PubMed ID: 21883757
[TBL] [Abstract][Full Text] [Related]
6. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
[TBL] [Abstract][Full Text] [Related]
7. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.
Ranganathan K; Worley S; Michaels MG; Arrigan S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet SC; Faro A; Danziger-Isakov L
J Heart Lung Transplant; 2009 Oct; 28(10):1050-6. PubMed ID: 19782286
[TBL] [Abstract][Full Text] [Related]
9. Impact of cytomegalovirus match on survival after cardiac and lung transplantation.
Bonatti H; Tabarelli W; Ruttmann E; Kafka R; Larcher C; Höfer D; Klaus A; Laufer G; Geltner C; Margreiter R; Müller L; Antretter H
Am Surg; 2004 Aug; 70(8):710-4. PubMed ID: 15328806
[TBL] [Abstract][Full Text] [Related]
10. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
Potena L; Holweg CT; Chin C; Luikart H; Weisshaar D; Narasimhan B; Fearon WF; Lewis DB; Cooke JP; Mocarski ES; Valantine HA
Transplantation; 2006 Aug; 82(3):398-405. PubMed ID: 16906040
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.
Kirklin JK; Naftel DC; Levine TB; Bourge RC; Pelletier GB; O'Donnell J; Miller LW; Pritzker MR
J Heart Lung Transplant; 1994; 13(3):394-404. PubMed ID: 8061014
[TBL] [Abstract][Full Text] [Related]
12. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
14. Does cytomegalovirus serology impact outcome after pediatric heart transplantation?
Mahle WT; Fourshee MT; Naftel DM; Alejos JC; Caldwell RL; Uzark K; Berg A; Kanter KR;
J Heart Lung Transplant; 2009 Dec; 28(12):1299-305. PubMed ID: 19783178
[TBL] [Abstract][Full Text] [Related]
15. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
16. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
[TBL] [Abstract][Full Text] [Related]
17. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
18. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
19. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
